Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$3.00 – $4.02
16% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $61.4M | $54.2M | $56.1M | $60.0M | $61.5M | $63.1M | $56.6M | $56.5M |
| Cost of revenue | $2.6M | $1.9M | $3.6M | $4.0M | $5.0M | $7.6M | $9.0M | $32.5M |
| Gross profit | $58.8M | $52.2M | $52.5M | $56.0M | $56.5M | $55.5M | $47.6M | $24.0M |
| Gross margin | 95.8% | 96.4% | 93.5% | 93.4% | 91.9% | 87.9% | 84.1% | 42.5% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $7.6M | −$4.6M | −$12.1M | −$6.3M | −$13.4M | −$10.3M | −$7.7M | −$4.2M |
| EBITDA | $37.6M | $20.5M | $24.4M | $25.2M | $17.3M | $12.9M | $17.2M | $18.0M |
| Net income | −$24.8M | −$19.6M | −$15.3M | −$13.1M | −$23.6M | −$27.5M | −$19.7M | −$12.6M |
| Net margin | -40.4% | -36.1% | -27.3% | -21.9% | -38.4% | -43.6% | -34.7% | -22.4% |
| EPS (diluted) | -0.92 | -0.67 | -0.48 | -0.41 | -0.73 | -0.85 | -0.62 | -0.40 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $58M | $-0.20 | $-0.21–$-0.20 | 1 |
| 2027 | $64M | $-0.03 | $-0.03–$-0.03 | 1 |
| 2028 | $77M | $0.07 | $0.07–$0.07 | 1 |
| 2029 | $84M | $0.24 | $0.23–$0.25 | 1 |
Forward consensus · source: Financial Modeling Prep
HLS THERAPEUTICS INC
No one on the platform currently holds HLTRF.
No tracked institution reports a position in HLTRF as of their last filing.
No one on the platform has traded HLTRF yet.
| $96M |
| — |
| LDXHFLumos Diagnostics Holdings Ltd. | $0.08 | +0.00% | $61M | — |
| LOVFFCannara Biotech Inc. | $1.21 | +5.52% | $120M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.8× sales vs its 2.1× historical median P/S.
Fair value ≈ $3.67 · price $3.16 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.